# Common gene mutations in 103 authenticated colorectal cancer cell lines

**Authors:** Christian Kranjec, Ina A. Eilertsen, Luís Nunes, Seyed H. Moosavi, Kaja C. G. Berg, Mette Eknæs, Merete Hektoen, Barbara Niederdorfer, Guro E. Lind, Rolf I. Skotheim, Anita Sveen, Ragnhild A. Lothe

PMC · DOI: 10.1038/s41389-026-00599-0 · Oncogenesis · 2026-01-27

## TL;DR

This study provides mutation profiles for 103 colorectal cancer cell lines to help researchers choose appropriate models for their studies.

## Contribution

The study presents authenticated mutation data for 20 CRC-relevant genes in 103 cell lines, highlighting hypermutation patterns and genetic interactions.

## Key findings

- Hypermutated cell lines show stronger mutational divergence and more subclonal mutations.
- Non-hypermutation mutations are often homozygous or hemizygous and under stronger selection pressure.
- Loss of heterozygosity is mainly observed in tumor suppressor genes.

## Abstract

Colorectal cancer (CRC) cell lines represent the main molecular subtypes of tumors and are valuable models for preclinical investigations. However, cell lines can diverge over time and careful selection of models based on their molecular features is key. We have authenticated 103 commonly used CRC cell lines and present the mutation profiles of 20 CRC-relevant genes sequenced to an average depth of 575 times coverage. The cell lines reflected the distinct mutation patterns of hypermutation phenotypes associated with microsatellite instability and pathogenic POLE mutations. Hypermutated cell lines appeared to have a stronger mutational divergence and more frequent subclonal mutations, while mutations not associated with hypermutation were more frequently homozygous or hemizygous, classified as pathogenic, and subject to stronger selection pressure. Loss of heterozygosity at mutated loci was primarily observed in tumor suppressor genes. Genetic interactions based on co-occurring mutations identified cell lines representative of particularly aggressive subtypes of CRC, including concurrent BRAF p.V600 and truncating APC mutations, as well as APC/TP53/RAS triple mutations with double hits of APC. This study provides a resource to guide the selection of cell lines for functional studies of CRC, and detailed mutation data including classifications of pathogenicity, variant allele frequencies and illustrations of the mutation distribution along the length of encoded proteins are included.

## Linked entities

- **Genes:** POLE (DNA polymerase epsilon, catalytic subunit) [NCBI Gene 5426], BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673], APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324], TP53 (tumor protein p53) [NCBI Gene 7157], ras (resistance to audiogenic seizures) [NCBI Gene 19412]
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}
- **Diseases:** CRC (MESH:D015179), tumor (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12901148/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12901148/full.md

---
Source: https://tomesphere.com/paper/PMC12901148